Clinical trials: Persistent Asthma
Asthma
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-38518168 compared with placebo in participants with persistent asthma that is inadequately…
- Trial name
- NCT01823016
- Testing
- JNJ-38518168
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 166 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a…
- Trial name
- NCT00270348
- Testing
- ciclesonide
- Volunteers
- 450 people
- Sponsor
- Sanofi
Asthma
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
- Trial name
- QAB149 (NCT01959412)
- Testing
- Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma
- Trial name
- NCT00598104
- Testing
- QAX576
- Sponsor
- Novartis
Asthma
A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study.
- Trial name
- NCT00859404
- Testing
- oglemilast
- Where
- India
- Volunteers
- 282 people
- Sponsor
- Glenmark Pharmaceuticals Europe Ltd. (R&D)
Asthma
Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)
This study is being conducted to demonstrate the non-inferiority between two inhaled glucocorticosteroids and long-acting bronchodilator combination drugs called mometasone furoate/formoterol fumarate in a metered-dose inhaler…
- Trial name
- NCT00424008
- Testing
- Mometasone furoate/formoterol (MF/F) MDI, Fluticasone propionate/salmeterol (F/SC) DPI
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
Evaluation of Dupilumab in Children With Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (<) 12 years of age with uncontrolled persistent asthma.
- Trial name
- VOYAGE (NCT02948959)
- Testing
- Dupilumab, Asthma Controller Therapies, Asthma Reliever Therapies
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Asthma
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting…
- Trial name
- NCT01493882
- Testing
- JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Persistent Asthma
Efficacy, Safety, and Pharmacokinetics of QAW039
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
- Trial name
- NCT01253603
- Testing
- QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
- Trial name
- NCT01453296
- Testing
- GW642444
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
This study is a multi-centre, randomised, double-blind, placebo-controlled (with rescue medication), two period crossover study in subjects with persistent uncontrolled asthma, currently not treated with an inhaled corticosteroid…
- Trial name
- NCT02567708
- Testing
- GSK2269557 DPI
- Where
- 12 sites in Germany
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Mild Persistent Asthma, Uncomplicated
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
The purpose of this study is to test the hypothesis that 18-22 week treatment with the inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild asthma, compared to placebo.
- Trial name
- NCT01804218
- Testing
- Nadolol
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Invion, Inc.